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Abstract
Background: The present study examined the role of microRNA (miR)-96 in renal cell carcinoma (RCC) invasion.
Methods: The expression of miR-96 was detected by quantitative reverse transcription-polymerase chain reaction in
human RCC cell lines with high (Caki-1) and low (786-O) metastatic potential. Invasive ability and Ezrin expression were
assessed in Caki-1 and 786-O cells transfected with a miR-96 mimic or inhibitor using wound healing assays, Transwell
assays and western blotting. Expression of miR-96 and Ezrin was also examined in primary RCC samples from 17
patients with metastatic disease and 46 patients who maintained remission during a follow-up period of 37 months.
Results: miR-96 expression was significantly lower in Caki-1compared to786-O cells. The invasive ability of Caki-1 and
786-O cells increased following transfection of cells with miR-96 inhibitor, whereas it decreased following transfection
with miR-96 mimic. Ezrin levels were negatively correlated with miR-96 in RCC, and inhibition of Ezrin expression
suppressed the miR-96-induced change in invasive ability. The negative correlation between miR-96 and metastasis/
Ezrin expression was also observed in human RCC specimens.
Conclusions: These results suggest that miR-96 suppresses RCC invasion by modulating Ezrin expression.
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Background
Despite improvements in available treatments, the progno-
sis remains poor for locally advanced and metastatic renal
cell carcinoma (RCC) [1]. Thus, it is critical to identify the
molecules controlling the invasive and metastatic potential
of RCC, which may provide new targets for intervention.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that play a key role in cancer progression [2].
miRNAs regulate the expression of many invasion and
metastasis-related genes in various types of malignancies
[3–5]. Among miRNAs, microRNA-96 (miR-96) was re-
cently shown to be involved in the invasive and metastatic
potential of hepatocellular carcinoma [6, 7], breast cancer
[8, 9], lung cancer [10],pancreatic cancer [11] and bladder
cancer [12]. To the best of our knowledge, the relationship
between miR-96 and RCC invasion or metastasis has not
been investigated. In the present study, we explored the
role of miR-96 in RCC invasion and metastasis.
The expression of miR-96 was detected in RCC cell
lines and clinical samples with different metastatic po-
tential. Our data indicated that miR-96 expression was
negatively correlated with the metastatic potential of
RCC, and overexpression of miR-96 by transfection with
synthetic miR-96 oligonucleotides decreased the invasive
potential of RCC cells.
Ezrin has been recognized as a molecular linker between
the actin cytoskeleton and plasma membrane, and is
involved in the maintenance of cell adhesion and cell
movement. Increasing evidence has shown that Ezrin is as-
sociated with metastasis of various human malignancies
[13–22]. The in silico analysis of Ezrin and miRNAs using
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three prediction programs, TargetScan, miRanda and Pic-
Tar, revealed that Ezrin is a target of miR-96. We hy-
pothesized that miR-96 may suppress RCC cell invasion
via regulation of Ezrin expression and verified this hypoth-
esis in the present study. Ezrin level was shown to be nega-
tively correlated with miR-96 in RCC cell lines, and
inhibition of Ezrin expression suppressed the miR-96-
induced change in invasive ability. The negative correlation
between miR-96 and metastasis/Ezrin expression was also
observed in human RCC specimens. These results suggest
that miR-96 may suppress RCC invasion through the
modulation of Ezrin expression.
Methods
Cell culture
Caki-1 and 786-O, which are human RCC cell lines with
high and low metastatic potential, respectively, were pur-
chased from the Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). Caki-1 cells were
cultured in McCoy’s 5A medium (Gibco, Grand Island,
NY, U.S.) supplemented with 15 % fetal bovine serum
(FBS; Shanghai Sangon Biological Engineering Technology
and Services Co., Ltd., Shanghai, China), and 786-O cells
were cultured in RPMI 1640 (Wisent, Saint-Jean-Baptiste,
Canada) supplemented with 10 % FBS.
Clinical sample collection
Human kidney specimens were obtained from 63 patients
who underwent radical nephrectomy for localized clear
cell RCC at the General Hospital of Jinan Military Com-
mand in China between 2008 and 2013. The collection
and use of the samples were reviewed and approved by
the Institutional Ethics Committee of General Hospital of
Jinan Military Command, and expedited pathological diag-
nosis and staging of these specimens were performed
prior to sampling and transporting them for research.
Histological diagnosis was established according to the
guidelines of the World Health Organization [23]. Cases
were selected according to tissue availability and were not
stratified for any known preoperative or pathological prog-
nostic factor. Clinical follow-up data was available for all
patients. The median follow-up period for all cases was
37 months (range, 7–65 months). Under the supervision
of an experienced pathologist, 63 renal cancer tissue sam-
ples were collected (before any treatment was begun) from
surgically resected kidneys and immediately stored in
liquid nitrogen until RNA or protein extraction.
Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen Life Technologies, Carlsbad, CA, U.S.) accord-
ing to the manufacturer’s protocol. The expression of
miR-96 was measured using the Hairpin-it™ miRNAs
qPCR Quantitation Kit (GenePharma, Shanghai, China)
with the following primers: Sense 5′-TTTGGCACTAGC
ACAT-3′; antisense 5′-GAGCAGGCTGGAGAA-3′. The
miRNA synthetic standard in the kit was used as a positive
control, according to the manufacturer’s instructions. U6
small nuclear RNA was used as an internal control, with
the following primers: Sense 5′-ATTGGAACGATACAG
AGAAGAT-3′; antisense 5′-GGAACGCTTCACGAATT
T-3′ (GenePharma, Shanghai, China). The relative expres-
sion of miR-96 in tissues and cell lines were calculated by
the 2-Δct method.
Transfection
Caki-1 and 786-Ocells were transiently transfected with
miR-96 inhibitor, miR-96 mimic and miR-control RNA
using Lipofectamine 2000 (Invitrogen). Inhibitor of miR-
96 (sequence: 5′-GCAAAAAUGUGCUAGUGCCAAA-
3′), mimic of miR-96 (sequence: 5′-UUUGGCACUAGC
ACAUUUUUGC-3′) and negative miR-control (se-
quence: 5′-CAGUACUUUUGUGUAGUACAA-3′) were
purchased from GenePharma. The negative miR-control
sequence was non-homologous to any human genomic
sequence in order to eliminate potential non-sequence-
specific effects as previously reported [24]. RCC cells
were seeded in six-well plates and transfected with 4 nM
of miR-96 inhibitor, miR-96 mimic or miR-control.
Wound healing assay
Caki-1 and 786-O cells transfected with miR-96 mimic,
inhibitor or miR-control were cultured as monolayers,
synchronized by starving the cells for 24 h in Dulbecco’s
Modified Eagle Medium (Gibco) containing 0.1 % FBS,
and wounded by removing a wide strip (approximately
300 μm) of cells across the well with a standard 200 μl
pipette tip. Wounded monolayers were washed twice to
remove nonadherent cells. Wound healing was moni-
tored by phase-contrast microscopy after 24 h culture in
1 % FBS, quantified using Image J software and
expressed as the mean percentage of the remaining cell-
free area compared with the area of the initial wound.
Transwell assay
The invasive ability of Caki-1 and 786-O cells trans-
fected with miR-96 mimic, inhibitor or miR-control was
determined using Matrigel (BD Pharmingen, San Diego,
CA, U.S.)-coated 24-well Transwell chambers, with
upper and lower culture compartments separated by
polycarbonate membranes with 8-μm pores (Corning,
Costar, New York City, U.S.). The bottom chamber was
filled with RPMI-1640 medium containing 10 % FBS for
786-Ocells or McCoy’s5A medium with 15 % FBS for
Caki-1 cells. The transfected cells (1 × 105) were seeded
on the top chamber and incubated at 37 °C with 5 %
CO2. After 40 h, the cells were removed from the upper
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surface by scrubbing with a cotton swab, and cells that
had migrated to the underside of the membrane were
stained with Giemsa (Sigma-Aldrich Co., St. Louis, MO,
U.S.). A total of five high-power fields were counted by
two independent blinded pathologists, and the mean
number of cells per field was calculated. The experi-
ments were performed in triplicate.
To further investigate the role of Ezrin in the inhibition
of invasion by miR-96, Caki-1 and 786-O cells were pre-
treated for 30 min with 10 μM NSC668394, a small mol-
ecule inhibitor of Ezrin [25], followed by transfection with
miR-control or miR-96 inhibitor for 24 h. Invasive ability
was then examined by Transwell assay as described above.
Western blot analysis
Ezrin expression was assessed by western blotting using
standard protocols. Briefly, equal amounts of extracted
protein, as determined by Bradford protein assay (Bio-Rad,
Hercules, CA, U.S.), were separated by sodium dodecyl
sulfate (SDS)-8 % polyacrylamide gel electrophoresis and
blotted onto polyvinylidene difluoride membranes (GE
Healthcare, Little Chalfont, England). Membranes were
probed with Ezrin antibody (Abcam, Cambridge, MA,
U.S.). After incubation with peroxidase-coupled secondary
antibodies (Abcam), blots were developed using enhanced
chemiluminescence reagents and exposed to X-ray films to
detect labeled proteins. Membranes were then stripped
with Re-Blot Plus (Millipore, Billerica, MA, U.S.) and
subsequently reprobed for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Abcam) as a loading control.
Data analysis
Negative and positive controls were routinely incorporated
for quality control in all the above assays. All analyses were
performed using SPSS 13 software. Repeated-measures
analysis of variance (ANOVA) tests were used to compare
multiple groups and p values <0.05 were considered statis-
tically significant. Results are expressed as mean ± standard
deviation.
Results
Expression of miR-96 in RCC cell lines with varying
metastatic potential
To evaluate the relationship between miR-96 expression
and metastatic potential, miR-96 levels were measured
Fig. 1 miR-96 expression in renal cell carcinoma (RCC) cell lines with
varying metastatic potential. miR-96 expression was detected by
quantitative reverse transcription-polymerase chain reaction (RT-PCR).
U6 small nuclear RNA was used as an internal control (*p < 0.05)
Fig. 2 miR-96 expression changes in Caki-1(a) and 786-O (b) cells
following transfection with miR-96 inhibitor or miR-96 mimic
compared to miR-control-transfected cells. miR-96 expression in RCC
cell lines was detected by quantitative RT-PCR after transfection with
the indicated constructs for 24 h (*p < 0.05)
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in RCC cell lines with varying metastatic potential by
qRT-PCR. The results showed that miR-96 was expressed
at a low level in Caki-1 cells with high metastatic potential
and at a high level in 786-O cells with low metastatic
potential (0.6 ± 0.08 vs. 2.9 ± 0.26, respectively; P < 0.05;
Fig. 1). These findings provide evidence that miR-96
expression is correlated with the metastatic phenotype of
RCC cells.
Impact of miR-96 expression on in vitro invasion by RCC cells
As shown in Fig. 2, miR-96 expression was significantly
down- or upregulated in Caki-1 and 786-O cells trans-
fected with the miR-96 inhibitor or miR-96 mimic,
respectively, compared to miR-control-transfected cells.
To evaluate the effect of changes in the levels of miR-
96 on the invasive ability of RCC cells in vitro, functional
assays were performed. Cell migration was assessed by
wound healing assay, which showed that Caki-1 and
786-O cells transfected with the miR-96 mimic migrated
at a slower rate (Caki-1: 42.2 % ± 2.7 % vs. 63.3 % ±
5.87 %, P < 0.05; 786-O: 26.9 % ± 6.35 % vs. 44.4 % ±
5.88 %, P < 0.05; Fig. 3), whereas cells transfected with
miR-96 inhibitor migrated at a faster rate (Caki-1:
87.2 % ± 4.81 % vs. 63.3 % ± 5.87 %, P < 0.05; 786-O:
86.8 % ± 7.99 % vs. 44.4 % ± 5.88 %, P < 0.05; Fig. 3),
compared to cells transfected with negative miR-control.
The impact of miR-96 on the invasive ability of RCC
cells was assessed by Transwell assay. As shown in Fig. 4,
Fig. 3 Migration of Caki-1 and 786-O cells transfected with miR-96 inhibitor or miR-96 mimic compared to miR-control-transfected cells. Wound
healing assay of Caki-1 cells (a) and 786-O cells (b) transfected with miR-96 inhibitor, miR-96 mimic or miR-control for 24 h. Percent healing at
24 h was calculated as the mean percentage of the remaining cell-free area compared with the area of the initial wound and showed that migration
of Caki-1 (c) and 786-O (d) cells increased following transfection with miR-96 inhibitor, and decreased following transfection with miR-96
mimic, compared to cells transfected with miR-control (*p < 0.05)
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the number of Caki-1 and 786-O cells that invaded through
the Matrigel-coated membrane was significantly higher for
cells transfected with miR-96 inhibitor(Caki-1:716 ± 62 vs.
424 ± 40, P < 0.05; 786-O: 815 ± 88.7 vs. 160 ± 23.1, P <0.05,
but was significantly lower for cells transfected with miR-96
mimic (Caki-1:52.2 ± 14.9 vs. 424 ± 40, P < 0.05; 786-O:
40.6 ± 9.71 vs. 160 ± 23.1, P < 0.05), compared to cells trans-
fected with negative miR-control.
MiR-96 suppresses RCC cell invasion by modulating Ezrin
expression
Ezrin expression was detected by western blotting in
Caki-1 and 786-O cells transfected with miR-96 mimic,
miR-96 inhibitor or miR-control. As shown in Fig. 5,
Ezrin was significantly downregulated in Caki-1 and
786-O cells transfected with miR-96 mimic(Caki-
1:0.83 ± 0.08 vs. 1.87 ± 0.18, P < 0.05; 786-O: 0.47 ±
0.04 vs.0.94 ± 0.27, P < 0.05, and was significantly
upregulated in cells transfected with miR-96 inhibi-
tor(Caki-1:2.67 ± 0.35 vs. 1.87 ± 0.18, P < 0.05; 786-O:
2.02 ± 0.39 vs.0.94 ± 0.27, P < 0.05), compared to miR-
control-transfected cells.
As shown in Fig. 6, there was no significant change in
the number of NSC668394-pretreated Caki-1 and 786-O
cells invading through the Matrigel after transfection
with miR-96 inhibitor or miR-control.
Fig. 4 Invasive ability of Caki-1 and 786-O cells transfected with miR-96 inhibitor or miR-96 mimic. Caki-1 cells (a) and 786-O cells (b) were transfected
with miR-96 inhibitor, miR-96 mimic or miR-control for 24 h and invasion was examined by Transwell assay. Invasive ability calculated as the mean
number of invading cells per field was increased in Caki-1 (c) and 786-O (d) cells following transfection with miR-96 inhibitor and decreased following
transfection with miR-96 mimic, compared to cells transfected with miR-control (*p < 0.05)
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Association of miR-96 levels with Ezrin expression and
metastasis in human renal cancer specimens
To further investigate the relationship among levels of
miR-96, Ezrin and metastasis in a clinical setting, 63
human localized clear cell RCC specimens were ana-
lyzed. Using 2010 AJCC TNM staging, there were 39
stage 1 and 24 stage 2 patients. Furhman grades of the
63 RCC were 9 of grade Furhman1, 27 of Furhman 2, 19
of Furhman 3 and 8 of Furhman 4. Seventeen patients
developed metastasis, whereas the remaining 46 main-
tained remission during a median follow-up period of
37 months. The expression levels of miR-96 and Ezrin
were compared between patients who developed metas-
tasis and those in remission. As shown in Fig. 7,
metastatic patients showed lower levels of miR-96 (P <
0.05) and higher levels of Ezrin expression (P < 0.05).
Pearson correlation analysis of the association between
miR-96 and Ezrin in these 63 patients showed a correl-
ation coefficient of–0.69 (P < 0.05).
Discussion
The present study showed that miR-96 expression was
negatively correlated with the metastatic potential of
RCC cells, and overexpression of miR-96 with synthetic
miR-96 oligonucleotides decreased the invasive potential
of RCC cells. These results suggest that miR-96 may
function as a tumor-suppressing miRNA in renal cancer.
To the best of our knowledge, this is the first study
investigating the relationship between miR-96 and inva-
sion in renal cancer cells. The impact of miR-96 on
tumors has been reported previously in other types of
cancer. Yu et al. showed that miR-96 directly targets the
KRAS oncogene and functions as a tumor-suppressor
miRNA in pancreatic cancer cells, where it decreased
cancer cell invasion and migration and slowed tumor
growth by downregulating KRAS [11]. Vishuamitra et al.
found that transfection of cell lines with miR-96
decreased proliferation, colony formation, and migration
of anaplastic lymphoma kinase-expressing cancer cells
[26]. miR-96 was also shown to function as a tumor-
promoting miRNA by increasing the invasive ability of
tumors in hepatocellular carcinoma cells [7], human
bladder urothelial carcinomas [12], non-small cell lung
cancer [10], and breast cancer [9]. Xu et al. showed that
miR-96 expression was positively correlated with liver
metastasis in colorectal cancer [27]. Based on the above
studies, it appears that miR-96 may work either as a
tumor suppressor or promoter, depending on the tumor
cell type.
Previous studies have compared miRNA profile changes
between metastatic RCC and primary tumors by miRNA
microarray [28–31]. However, in those studies, miR-96
did not show significant differences in expression between
RCC metastases and primary tumors, which differs from
our present results. One possible explanation for this
discrepancy is that in the present study, we compared the
expression of miR-96 between primary RCC samples of 17
patients who developed metastasis and 46 patients who
maintained remission for 37 months, whereas in the stud-
ies by Heinzelmann et al. [31], Jung et al. [28] and White
et al. [29], miRNA expression was compared between
matched metastatic RCC and primary RCC samples in the
same patients. Wu et al. compared miRNA expression
between T1 and T4 stage RCC samples [30]. Another pos-
sible reason for the differences in the results of these
various studies is the different sensitivity of miRNA
microarray vs. qRT-PCR for the detection of changes in
miRNA expression, as well as differences in the definition
Fig. 5 Expression of Ezrin in Caki-1 and 786-O cells transfected with
miR-96 mimic, miR-96 inhibitor or miR-control. a Ezrin was detected by
western blotting using GAPDH as a loading control. b Ezrin expression
increased following transfection of cells with miR-96 inhibitor, and
decreased following transfection with miR-96 mimic, compared to cells
transfected with miR-control. IntDen ratio represents the integrated
density ratio of Ezrin to GAPDH as quantified by Image J (*p < 0.05)
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of what constitutes a significant difference in miRNA
expression among the studies. Even the studies by
Heinzelmann et al. [31], Jung et al. [28] and White et
al. [29], which compared miRNA expression between
matched metastatic and primary RCC samples, showed
different miRNA profiles in the same types of samples.
In another report by Heinzelmann et al. [32], the
miRNA profiles of patients who developed metastasis
were compared to those of patients who maintained
remission during a specific follow-up period, similar to
the present study; however, differential expression of
miR-96 was not detected. It is possible that the sample
size of our present study and that of Heinzelmann et al.
may not have been great enough to eliminate the
impact of sampling bias.
There were several limitations in our present study.
Our results showed a negative correlation between Ezrin
and miR-96; however, the precise mechanism by which
miR-96 affects Ezrin expression is not clear and warrants
further investigation. Furthermore, additional pathways
may be involved in miR-96 regulation of invasion in
RCC. In vivo studies will be required to verify that the
progression of RCC can be inhibited by miR-96.
Patients diagnosed at the metastatic stage of RCC have
a relatively poor prognosis, with a five year survival rate
of only 11.9 % in 2001 in North America [33]. Even in
Fig. 6 Invasive ability detected by Transwell assay of Ezrin inhibitor-pretreated Caki-1 (a) and 786-O (b) cells transfected with miR-96 inhibitor
or miR-control. RCC cells were pretreated with 10 μM of Ezrin inhibitor NSC668394 for 30 min, followed by transfection with miR-control or
miR-96 inhibitor for 24 h. No significant change in mean invading cells per field of NSC668394-pretreated Caki-1 (c) and 786-O (D) cells was
observed after transfection with miR-96 inhibitor or miR-control (Δp>0.05)
Yu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:107 Page 7 of 9
the era of targeted therapy, the median survival for clear
cell metastatic RCC has only improved from 11 to
14 months [34]. Further investigation of the potential
suppression of RCC invasion by miR-96 and its effect on
the downregulation of Ezrin expression may offer
novel therapeutic targets to prevent invasion and
metastasis of RCC.
Conclusions
In conclusion, it was found that expression of miR-96 was
negatively correlated with the metastatic ability of RCC,
and that downregulation of miR-96 could suppress the
invasion of renal cancer cell via downregulation of Ezrin
expression.
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